Allspring Global Investments Holdings LLC Has $683,000 Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Allspring Global Investments Holdings LLC raised its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 87,155 shares of the medical instruments supplier’s stock after purchasing an additional 5,295 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.22% of AngioDynamics worth $683,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Gladius Capital Management LP acquired a new stake in AngioDynamics in the 3rd quarter valued at approximately $30,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of AngioDynamics by 37.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,105 shares of the medical instruments supplier’s stock valued at $67,000 after purchasing an additional 2,491 shares during the last quarter. Dark Forest Capital Management LP bought a new stake in shares of AngioDynamics in the third quarter worth $85,000. CTC Alternative Strategies Ltd. acquired a new position in AngioDynamics during the third quarter worth $92,000. Finally, Laurion Capital Management LP bought a new position in AngioDynamics in the third quarter valued at $110,000. 89.43% of the stock is currently owned by institutional investors.

Insider Activity

In other AngioDynamics news, CEO James C. Clemmer bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were acquired at an average cost of $6.70 per share, with a total value of $67,000.00. Following the acquisition, the chief executive officer now owns 539,066 shares of the company’s stock, valued at $3,611,742.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. HC Wainwright reduced their price objective on shares of AngioDynamics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, January 8th. Raymond James reduced their price target on AngioDynamics from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, January 9th. Finally, Oppenheimer raised AngioDynamics from a “market perform” rating to an “outperform” rating and set a $12.00 price target on the stock in a research report on Friday, April 5th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.25.

AngioDynamics Stock Performance

AngioDynamics stock opened at $5.87 on Thursday. The stock has a 50-day simple moving average of $5.93 and a 200 day simple moving average of $6.42. The stock has a market capitalization of $235.15 million, a P/E ratio of -1.21 and a beta of 0.66. AngioDynamics, Inc. has a 52 week low of $5.26 and a 52 week high of $11.38.

AngioDynamics Company Profile

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.